To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: FDA Approves Aromasin For Advanced Breast Cancer URL: http://www.pslgroup.com/dg/13E44A.htm Doctor's Guide October 25, 1999
PEAPACK, N.J. -- October 25, 1999 -- Pharmacia & Upjohn has received U.S. Food and Drug Administration (FDA) approval for Aromasin (exemestane tablets), a new treatment for advanced breast cancer in postmenopausal women.
Developed by Pharmacia & Upjohn, Aromasin is the first aromatase inactivator for use in advanced breast cancer in patients whose tumors stop responding to tamoxifen therapy. Aromasin was generally well-tolerated in clinical trials. The most common drug-related adverse events were hot flashes, nausea, fatigue, increased sweating, and increased appetite.
Aromasin is Pharmacia & Upjohn's second new treatment for breast cancer to receive FDA approval this year. Earlier this month, the company launched Ellence (epirubicin hydrochloride injection) in the U.S. as a component of adjuvant therapy in the treatment of primary breast cancer. Ellence, which received FDA approval in September, is the first and only chemotherapy agent for treatment of early node-positive breast cancer following surgery. As with other chemotherapy agents in this class, there is an increased risk of treatment-related leukemia and congestive heart failure (incidents of 0.8 percent and 1.5 percent respectively in clinical trials). --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.